Laboratory Safety of Dupilumab in Patients Aged 6–11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial

Laboratory Safety ◽

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

American Journal of Clinical Dermatology ◽

10.1007/s40257-021-00618-3 ◽

2021 ◽

Author(s):

Eric L. Simpson ◽

Jonathan I. Silverberg ◽

Audrey Nosbaum ◽

Kevin L. Winthrop ◽

Emma Guttman-Yassky ◽

...

Keyword(s):

Clinical Trial ◽

Atopic Dermatitis ◽

Phase Ii ◽

Safety Analysis ◽

Phase Iii ◽

Clinical Trial Program

Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

American Journal of Clinical Dermatology ◽

10.1007/s40257-021-00638-z ◽

2021 ◽

Author(s):

Eric L. Simpson ◽

Jonathan I. Silverberg ◽

Audrey Nosbaum ◽

Kevin L. Winthrop ◽

Emma Guttman-Yassky ◽

...

Keyword(s):

Clinical Trial ◽

Atopic Dermatitis ◽

Phase Ii ◽

Safety Analysis ◽

Phase Iii ◽

Clinical Trial Program

Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)

British Journal of Dermatology ◽

10.1111/bjd.18434 ◽

2019 ◽

Vol 182 (5) ◽

pp. 1120-1135 ◽

Cited By ~ 15

Author(s):

A. Wollenberg ◽

L.A. Beck ◽

A. Blauvelt ◽

E.L. Simpson ◽

Z. Chen ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase Iii ◽

Laboratory Safety ◽

Three Phase ◽

Phase Iii Trials

Faculty Opinions recommendation of Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732206793.793541028 ◽

2018 ◽

Author(s):

Carsten Flohr ◽

Teresa Tsakok

Keyword(s):

Clinical Trial ◽

Atopic Dermatitis ◽

Topical Corticosteroid ◽

Corticosteroid Treatment ◽

Phase Iii ◽

Inadequate Response ◽

Ciclosporin A

Faculty Opinions recommendation of Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732206793.793542091 ◽

2018 ◽

Author(s):

Hidehisa Saeki

Keyword(s):

Clinical Trial ◽

Atopic Dermatitis ◽

Topical Corticosteroid ◽

Corticosteroid Treatment ◽

Phase Iii ◽

Inadequate Response ◽

Ciclosporin A

NIH Announces Phase III Clinical Trial of Creatine for Parkinson's Disease

PsycEXTRA Dataset ◽

10.1037/e607462007-001 ◽

2007 ◽

Keyword(s):

Parkinson’S Disease ◽

Clinical Trial ◽

Parkinson's Disease ◽

Phase Iii ◽

Phase III Clinical Trial Comparing Iopamidol 250 mgI/mL and Iopamidol 300mgI/mL in Cerebral Angiography: Multicenteric, Randomized and Double Blind Study

Journal of the Korean Radiological Society ◽

10.3348/jkrs.2007.57.6.501 ◽

2007 ◽

Vol 57 (6) ◽

pp. 501

Author(s):

Hyobin Seo ◽

Moon Hee Han ◽

Bae Ju Kwon ◽

So Hyang Im ◽

Cheolkyu Jung ◽

...

Keyword(s):

Clinical Trial ◽

Cerebral Angiography ◽

Blind Study ◽

Phase Iii ◽

Double Blind Study ◽

Double Blind ◽

Faculty Opinions recommendation of Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725828169.793561106 ◽

2019 ◽

Author(s):

Mark Bower

Keyword(s):

Clinical Trial ◽

Kaposi's Sarcoma ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Kaposi’S Sarcoma ◽

Phase Iii ◽

Faculty Opinions recommendation of A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727289372.793551519 ◽

2018 ◽

Author(s):

Adil Bharucha

Keyword(s):

Clinical Trial ◽

Phase Iii ◽

Idiopathic Constipation ◽

Chronic Idiopathic Constipation

Faculty Opinions recommendation of A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727289372.793528809 ◽

2017 ◽

Author(s):

Aldo Infantino

Keyword(s):

Clinical Trial ◽

Phase Iii ◽

Idiopathic Constipation ◽

Chronic Idiopathic Constipation